TY - JOUR
T1 - Discovery of Highly Potent Serotonin 5-HT2Receptor Agonists Inspired by Heteroyohimbine Natural Products
AU - Orr, Meghan J.
AU - Cao, Andrew B.
AU - Wang, Charles Tiancheng
AU - Gaisin, Arsen
AU - Csakai, Adam
AU - Friswold, Alec P.
AU - Meltzer, Herbert Y.
AU - McCorvy, John D.
AU - Scheidt, Karl A.
N1 - Funding Information:
We thank the National Institutes of Health (R21NS120521) and Northwestern University (K.A.S) and a Medical College of Wisconsin Research Affairs Counsel Pilot Grant (J.D.M.) for financial support. M.J.O. was supported by the NIH under award number F30DA050445. A.P.F. acknowledges support from Northwestern University’s Chemistry of Life Processes Institute.
Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/4/14
Y1 - 2022/4/14
N2 - The serotonin 5-HT2receptors are important pharmaceutical targets involved in signaling pathways underlying various neurological, psychiatric, and cardiac functions and dysfunctions. As such, numerous ligands for the investigation of these receptors' activity and downstream effects have been developed synthetically or discovered in nature. For example, the heteroyohimbine natural product alstonine exhibits antispychotic activity mediated by 5-HT2A/2Cagonism. In this work, we identified a heteroyohimbine metabolite containing a serotonin pharmacophore and truncated the scaffold, leading to the discovery of potent agonist activity of substituted tetrahydro-β-carbolines across the 5-HT2receptor family. Extensive SAR development resulted in compound 106 with EC50values of 1.7, 0.58, and 0.50 nM at 5-HT2A, 5-HT2B, and 5-HT2C, respectively. Docking studies suggest a πstacking interaction between the tetrahydro-β-carboline core and conserved residue Trp6.48as the structural basis for this activity. This work lays a foundation for future investigation of these compounds in neurological and psychiatric disorders.
AB - The serotonin 5-HT2receptors are important pharmaceutical targets involved in signaling pathways underlying various neurological, psychiatric, and cardiac functions and dysfunctions. As such, numerous ligands for the investigation of these receptors' activity and downstream effects have been developed synthetically or discovered in nature. For example, the heteroyohimbine natural product alstonine exhibits antispychotic activity mediated by 5-HT2A/2Cagonism. In this work, we identified a heteroyohimbine metabolite containing a serotonin pharmacophore and truncated the scaffold, leading to the discovery of potent agonist activity of substituted tetrahydro-β-carbolines across the 5-HT2receptor family. Extensive SAR development resulted in compound 106 with EC50values of 1.7, 0.58, and 0.50 nM at 5-HT2A, 5-HT2B, and 5-HT2C, respectively. Docking studies suggest a πstacking interaction between the tetrahydro-β-carboline core and conserved residue Trp6.48as the structural basis for this activity. This work lays a foundation for future investigation of these compounds in neurological and psychiatric disorders.
KW - Serotonin 5-HTreceptors
KW - heteroyohimbine metabolism
KW - small molecule agonists
KW - tetrahydro-β-carbolines
UR - http://www.scopus.com/inward/record.url?scp=85127900703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127900703&partnerID=8YFLogxK
U2 - 10.1021/acsmedchemlett.1c00694
DO - 10.1021/acsmedchemlett.1c00694
M3 - Article
C2 - 35450369
AN - SCOPUS:85127900703
SN - 1948-5875
VL - 13
SP - 648
EP - 657
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
IS - 4
ER -